Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (504)	5/2/2002 2:21:31 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 724

Book increased by 0.14/share. It's best, for long-term perspective, to keep an eye on what Eichenbaum is doing?? Large increase in inventories.

To: Tomato who wrote (504)	8/1/2002 1:40:35 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 724

Shareholder's equity up 2.4M, quarter to quarter, 3.4M, year to date, to $29.7M. Just looking at the report, first blush. $0.11/share profit, lower than I expected. Accounts payable and accrued expenses down 2.2M. Cash up 2.1M. First-half 2002 revenues of $29.4 million were relatively flat compared with $29.5 million last year. Adjusted to exclude fully custom-engineered bioprocess equipment and DGI revenues aggregating $4.1 million in last year's first half, net sales increased 16 percent for the 2002 six-months.